Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Durvalumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK | na | na | 5xj4:HL/5x8m:BC | null | null | 2,014 | 2015 | CD274 | Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine | Non-small cell lung cancer;Urogenital cancer;Small cell lung cancer | Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;Gastrointestinal cancer;Myelofibrosis;Vulvovaginal cancer | CNS cancer;Lymphoproliferative disorders;Thyroid cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSRYWMSWVR QAPGKG LEWVANIK QDGS EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REGG WFGELAFDY WGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQRVSSS YLAWYQ QKPGQAP RLLIYD ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSLPW TF GQGT KVEI K |
Dusigitumab | Whole mAb | G2 | Lambda | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMDVWGQGTTVTVSS | QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSAGRVFGGGTKLTVL | na | na | null | null | null | 2,012 | 2013 | IGF1&IGF2 | MedImmune | na | na | Breast cancer;Liver cancer;Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYDINWVRQ ATGQG LEWMGWM NPNSGNTGY AQKF QG RVTMT RNTS ISTAYMELS SLRSEDT AVYYCA RDPYY YYYGMDV WGQG TTVTVS S | QSVLTQPPS V SAAPGQ KVTISC SGSSSNIENN HVSWYQ QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGT SATLGITG LQTGDEA DYYCETW DTSLSAGR VF GGGT KLTV L |
Duvortuxizumab | Bispecific scFv with Crossover | na;na | Kappa;Lambda | Phase-I | Discontinued | QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS | ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,016 | 2017 | CD19;CD3E | Janssen Biotech;MacroGenics | na | na | Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma | Dual-Affinity Re-Targeting Technology | null | Q VTLRE SGPA LV KPTQ TLTLTCTF SG FSLS TSGM GVGWIR QPPGKA LEWLAHIWW DDDKRYNPALK SRLTIS KDTSKN QVFLTMT NMDPVDT ATYYCARMELWSY YFD YWGQGT TVTV SS | ENVL T QSPA TLSV TPGE KATITCR ASQS VSYMHWYQ QKPGQAP RLLIYD ASNRASGVPS R FSGSGSGTDH TLTISS LEAEDAA TYYCF QGS VY P FT FGQGT KLEI K |
Ebdarokimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVQSGAEVKKPGESLKISCQSSGYTFTSYWIGWVRQMPGQGLEWIGIMSPVDSDIRYNPMFRGQVTMSVDKSSSTAYLQWSSLKASDTAMYYCARRRPGQGYFDFWGQGTMVTVSS | EIVLTQSPATLSASPGERATISCRASQSVGTWVAWYQQKPGQAPRSLIYAASNLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYNIYPYTFGQGTRLEIK | na | na | null | null | null | 2,020 | 2021 | IL12B | Akeso Biopharma | na | Plaque Psoriasis;Ulcerative colitis;Systemic lupus erythematosus | Crohn's disease;Psoriatic arthritis | na | null | E VQLVQ SGA EVK KPGE SLKISCQ SSGY TFTSYWIGWVRQ MPGQGL EWIGIM SPVDSDI RY NPMFRG QVTMSV DKSSS TAYLQWSS LKASDT AMYYCAR RRPGQG YFDFW GQG TMVTVS S | E IVLTQ SPA TLS ASPGE RATISCR ASQSVG TWVAWYQ QKPGQAPR SLIYAA SNLQSGIP ARFS GSGSGTD FTLTIS SLEP ED FAVYYC Q QYNIY P Y T FGQGT RLEI K |
Eblasakimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARMPNWGSLDHWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYASFGQGTKVEIK | na | na | null | null | 4hwe:HL/4hwb:HL | 2,021 | 2022 | IL13RA1 | ASLAN Pharmaceuticals | na | Atopic dermatitis | na | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGY SFTSYWIGWVRQ MPGKGL EWMGVI YPGDSY TRY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCAR MPNWGSLDHWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSIS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQQY ASFGQGT KVEI K |
Ebronucimab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQLVESGGGLVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSGISSSSSYISYADSVQGRFTISRDNGKNSLYLQMNSLRAEDTALYFCAREYDFWSAYYDAFDVWGQGTMVTVSS | QSELTQPRSVSGSPGQSVTISCTGTSRNIGGGNDVHWYQQHPGKAPKLLISGVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCQSFDGSLSGSVFGTGTDVTVL | na | na | null | null | null | 2,020 | 2021 | PCSK9 | Akeso Biopharma | na | Heterozygous familial hypercholesterolemia | na | na | null | E VQLVES GGG LV QPGR SLRLSC AASGF TFSS Y SMNWVR QAPGKGL EWVS GISSSSS YISY ADSVQG RFTISR DNGKN SLYLQMN SLRAEDT ALYFCAR EYDF WSAYY DA FDV WGQG TMVTVS S | QSELTQPR SV SGSPGQ SVTISCT GTSRNIGGGND VHWYQ QHPGKAP KLLISGVIE RSSGVPDRFSGSKSGN TASLTIS GLQAEDEA DYYCQS FDGS L SG SVF GTGT DVTV L |
Eciskafusp | Fusion Protein | G1 | Kappa | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | PDCD1 | TBC | TBC | TBC | TBC | TBC | null | E VQLLES GGG LV QPGG SLRLSCA ASGF SF S SYTMSWVR QAPGKG LEWVATIS GGGRD IY YPDSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCVLL TGR VYFALD SWGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINCK ASESVDTSDNS FIHWYQ QKPGQSP KLLIYR SSTLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNYDVPW TF GQGT KVEI K |
Ecleralimab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYWMHWVRQAPGKGLEWVGHIKSKTDAGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCAREIYYYAFDSWGQGTLVTVSS | SYELTQPLSVSVALGQTARITCSGDNIGSKYVHWYQQKPGQAPVLVIYGDNERPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQAADWVDFYVFGGGTKLTVL | na | na | null | null | null | 2,021 | 2022 | TSLP | Novartis | na | Asthma | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TF SD YWMHWVR QAPGKGL EWVGHIKS KTDAGTTDYAAP VKGRFTISR DDSKN TLYLQMN SLKTEDT AVYYCA R EIYYYAF DSWGQG TLVTVS S | SYELTQP LSVSVA LGQ TARITC SGDNIGS KYVHWYQ QKPGQAP VLVIY GDNERPSGIPERFSGSNSGN TATLTISR AQAGDEA DYYCQ AADW VDFYVF GGGT KLTV L |
Ecromeximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVTLVESGGDFVKPGGSLKVSCAASGFAFSHYAMSWVRQTPAKRLEWVAYISSGGSGTYYSDSVKGRFTISRDNAKNTLYLQMRSLRSEDSAMYFCTRVKLGTYYFDSWGQGTTLTVSS | DIQMTQTASSLPASLGDRVTISCSASQDISNYLNWYQQKPDGTVKLLIFYSSNLHSGVPSRFSGGGSGTDYSLTISNLEPEDIATYFCHQYSKLPWTFGGGTKLEIK | na | na | null | null | null | 2,002 | 2003 | GD3 ganglioside | Kyowa Hakko;Kyowa Kirin;Life Science Pharmaceuticals;Ludwig Institute for Cancer Research | na | na | Malignant melanoma | na | null | E VTLVE SGGD FV KPGG SLKVSC AASGFA FSHYAMSWVR QTPAKR LEWVAYIS SGGSG TYY SDSVKG RFTISR DNAKN TLYLQMRSL RSEDS AMYFCTRVK LG TYYF DSWGQG TTLTVS S | DIQ MT QTASSLPASLGD RVTISC SASQD ISNYLNWYQ QKPDGT VKLLIFY SSNLHSGVPSRFSGGGSGTD YSLTI SNLE PEDIATYFCHQY SKLPWTFGGGT KLEI K |
Eculizumab | Whole mAb | G2 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK | na | na | 5i5k:HL:XY | null | null | 2,002 | 2003 | C5 | Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc | Neuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria | Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19 | Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus | GS Gene Expression System | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASG YIF SN YWIQWVR QAPGQG LEWMGEI LPGSGST EYT ENFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCARYF FGSSPN WYFDVW GQG TLVTVS S | DIQMTQSPSSL SA SVGD RVTITC GASEN IYGALNWYQ QKPGKAP KLLIYG ATNLADGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQN VLNTPL T FGQGT KVEI K |
Edrecolomab | Whole mAb | G2a | Kappa | Approved (w) | Discontinued | QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA | NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK | na | na | null | null | null | 1,995 | 1996 | EPCAM | Ajinomoto;Centocor Inc | Colorectal cancer | na | Adenocarcinoma;Pancreatic cancer | na | null | QV QLQ QSGA ELV RPGT SVKVSC KASG YAFTNYLIEWVK QRPGQGL EWIGVI NPGSGGTNYNEKFKG KATLTA DKSSST AYMQLS SLTSDDS AVYFCA RDGP WFAYW GQG TLVTVS A | N IVMT QSPKS MSM SVGE RVTLTCK ASEN VVTYVSWY QQKPEQSP KLLIYG ASNRYTGVPDRFTGSGSATD FTLTISSV QAEDLADYHCGQGYSYP YT FGGGT KLEI K |
Efalizumab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK | na | na | 3eo9:HL/3eoa:HL:BA/3eob:HL:BA | null | null | 2,001 | 2002 | ITGAL | Genentech;Merck Serono;XOMA | Psoriasis | na | Psoriatic arthritis;Type 1 diabetes mellitus | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY SFT G HWMNWVR QAPGKGL EWVGMI HPSDSETRYNQKFKD RFTISVD KSKN TLYLQMN SLRAEDT AVYYC ARG IYFY GT TYFD YWGQG TLVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASK TISKYLAWYQ QKPGKAP KLLIYS GSTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QHNEYPL T FGQGT KVEI K |
Efungumab | scFv | na | Kappa | Phase-III | Discontinued | EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS | DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK | na | na | null | null | null | 2,006 | 2007 | Heat Shock Protein 90 Homolog | NeuTec Pharma | na | na | Breast cancer;Candidiasis | na | null | E VQLVE SGA EVK KPGE SLRISC KGSG CIISSYWISWVR QMPGKGL EWMGK IDPGDS YINY SPSFQG HVTIS ADKSIN TAYLQWN SLKASDT AMYYCA RGGRDFGDS FDY WGQG TLVTV SS | DV VMT QSPS FLSAF VGD RITITCR ASSG ISRYLAWYQ QAPGKAP KLLIYA ASTLQTGVPSRFSGSGSGT EFTLTIN SLQ PEDFATYYCQH LNSYPL TF GGGT KVDI K |
Eglatoprutug | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYAQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRASESVDIYGQSFMHWYLQKPGQSPQLLIYLASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQNNEDPYTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | KIT | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGVIYS GNGDTSY AQK FKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR ERDTRFGNWGQ GTLVTVS S | DI VMT QSPLSLPVTPGEPA SISCR ASE SVDI YGQ SFMHWYL QKPGQSP QLLIYLA SNLESGVPDRFSGSGSGTD FTLKISRVE AED VGVYYCQ QNNEDPY T FGGG TKVEI K |
Eldelumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK | na | na | null | null | null | 2,013 | 2014 | CXCL10 | Bristol-Myers Squibb;Medarex | na | na | Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries | Medarex UltiMAb Mouse | null | QM QLVES GGG VV QPGR SLRLSCT ASG FTF SNNG MHWVRQ APGKGL EWVAVIWF DGMN KFYVD SVKG RFTISR DNSKN TLYLEMN SLRAED TAIYYCAR EGDGSG IYYYYGMD VWGQG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDFAVYYCQQ YGSSP IFTF GPGT KVDI K |
Elezanumab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSS | QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL | na | na | null | null | null | 2,016 | 2017 | RGMA | AbbVie | na | Multiple sclerosis;Spinal cord injuries;Stroke | na | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASG YTFTS HG ISWVR QAPGQGLD WMGWI SPYSGNTNY AQ K LQG RVTMTT DTSTS TAYMELS SLRSEDT AVYYCAR VGSGP YYYMDV WGQG TLVTVS S | QSALTQPR SV SGSPGQ SVTISCT GTSSSVGD SIYVSWYQ QHPGKAP KLMLYD VTKRPSGVPDRFSGSKSGN TASLTIS GLQAEDEAD YYCYSY AGTDT L FGGG TKVTV L |
Elgemtumab | Whole mAb | G1 | Kappa | Phase-I/II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK | na | na | null | null | 4p59:HL | 2,014 | 2015 | ERBB3 | MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology | na | na | Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours | Medarex HuMAb Mouse | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSAI NSQGK STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR WGDEGF DIW GQ GTLVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASQG ISNWLAWYQ QKPGKAP KLLIYG ASSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSSFPTTFGQGT KVEI K |
Elipovimab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSS | SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL | na | na | null | null | 4fq1:HL/4jy4:BA/4fqc:HL | 2,018 | 2019 | HIV-1 gp120 | Gilead Sciences | na | na | HIV infections | na | null | QM QLQE SGPGL V KPSE TLSLTCSV SGASISDS YWSWIR RSPGKGL EWIGYVHK SGDTNYNPSLK SRVHLSLD TSKN QVSLSLTGVT AADSGK YYCART LHGR RIYGIVAF NEWF TYFYMDV WGTGT QVTVS S | SDI SV APGE TARIS CGEKSLGS RAVQW YQ H RAGQAP SLIIY NNQDRPSGIPERFSGSPDSRPGT TATLTITSVE AGDE ADYYCHIW DSRVPT KWVF GGGT TLTV L |
Elotuzumab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK | na | na | null | null | null | 2,008 | 2009 | SLAMF7 | AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma | Multiple myeloma | na | na | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGFDFSR YWMSWVR QAPGKGL EWIGEI NPDSST IN YAPSLKD KFIISR DNAKNS LYLQMN SLRAEDT AVYYCA RPDGN YWYFDV WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQD VGIAVAWYQ QKPGKVP KLLIYWA STRHTGVPDRFSGSGSGTD FTLTIS SLQ PEDVAT YYC QQYSSYPY T FGQGT KVEI K |
Elranatamab | Bispecific mAb | G2;G2 | Kappa;Kappa | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAIGGSGGSLPYADIVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYQSWPLTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMTWVRQAPGKGLEWVAFIRNRARGYTSDHNPSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRPSYYVLDYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLFNVRSRKNYLAWYQQKPGQPPKLLISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYDLFTFGSGTKLEIK | None;None | None;None | None;None | 2,021 | 2022 | TNFRSF17;CD3E | Pfizer | na | Multiple myeloma | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFS SYPM SWVR QAPGKGL EWVSAI GGSGGSLPYAD IVK G RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARY WPMDIWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS YLAWYQ QKPGQAP RLLMYD A SIRA TGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYQSWPL TF GQGT KVEI K |
Eluvixtamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I | Discontinued | QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS | DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | CD33;CD3E | Amgen | na | na | Acute myeloid leukaemia | BiTE Technology | null | Q VQLVQ SGA EVK KPGE SVKVSCK ASGY TFTN YGM NWVK QAPGQGL EWMGWIN TYTGEPT Y ADKFQG RVTMTT DTSTS TAYMEIRN LGGDDT AVYYCARWS WSDG YYVYFD YWGQGT SVTVS S | D IVMT QSPDS LTVSL GER TTINC KSSQS VL DSSTNKNS LAWYQ QKPGQPP KLLLSWA STRESGIPDRFSGSGSGT DFTLTI DSPQPEDSA TYYCQ QSAHFP ITF GQGT RLEI K |
Emactuzumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK | na | na | 4liq:HL | null | null | 2,014 | 2015 | CSF1R | Roche;University of Texas M. D. Anderson Cancer Center | na | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours | Giant cell tumour of tendon sheath;Pigmented villonodular synovitis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYDISWVR QAPGQG LEWMGVIWT DGGTNY AQKL QG RVTMTT DTSTS TAYMELRS LRSDDT AVYYCA RDQ RLYFDVW GQGT TVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASEDVN TYVSWYQ QKPGKAP KLLIYAA SNRYTGVPSRFSGSGSGTD FTLTISS LQPEDF ATYYCQ QSFSYPTFGQGT KLEI K |
Emapalumab | Whole mAb | G1 | Lambda | Approved | NFD | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS | NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL | na | na | null | null | null | 2,016 | 2017 | IFNG | NovImmune SA;Swedish Orphan Biovitrum | Haemophagocytic lymphohistiocytosis | na | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDGSSG WYV PHW F DPWGQG TLVTVS S | NF ML TQPH SV SESPGK TVTISCT RSSGS I ASN YVQWYQ QRPGSSP TTVIY EDNQRPSGVPDRFS GSI DSSSNS ASLTIS GLKTEDEAD YYCQS YDGSNR WMF GGGT KLTV L |
Emerfetamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I | Active | QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS | DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | CD33;CD3E | Amgen | na | Acute myeloid leukemia | na | BiTE Technology | null | Q VQLVQ SGA EVK KPGE SVKVSCK ASGY TFTN YGM NWVK QAPGQ CLEWMGWIN TYTGEPT Y ADKFQG RVTMTT DTSTS TAYMEIRN LGGDDT AVYYCARWS WSDG YYVYFD YWGQGT SVTVS S | D IVMT QSPDS LTVSL GER TTINC KSSQS VL DSSTNKNS LAWYQ QKPGQPP KLLLSWA STRESGIPDRFSGSGSGT DFTLTI DSPQPEDSA TYYCQ QSAHFP ITF GCGT RLEI K |
Emicizumab | Bispecific mAb | G4;G4 | Kappa;Kappa | Approved | NFD | QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK | QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK | None;None | None;None | None;None | 2,015 | 2016 | F9;F10 | Chugai Pharmaceutical;Roche | Haemophilia A | na | na | na | null | Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TF TDNNMD WVR QAPGQGL EWMG DINTRSGG SIY NEEFQD RVIMTV DKSTD TAYMELSS LRSEDTA TYHCA RRKSY GYYL DEWGEG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASRN IERQLAWYQ QKPGQAP ELLIYQA SRKESGVPDRFSGSRYGTD FTLTIS SLQ PEDIATYYCQQ YSDPPL TF GGG TKVEI K |
Emibetuzumab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK | na | na | null | null | null | 2,014 | 2015 | MET | Eli Lilly | na | Gastric cancer;Non-small cell lung cancer;Cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYYMHWVRQ APGQG LEWMGRV NPNRRGTT Y NQ KFEGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR ANW L DYWGQG TTVTVS S | DI QMT QSPSS LSAS VGD RVTITCSV SSSVS SIYLHWYQ QKPGKAP KLLIYS TSNLASGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCQVY SGYP LTF GGG TKVEI K |
Emirodatamab | Bispecific scFv-scFv-scFc | na;na | Kappa;Lambda | Phase-I | Active | QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,022 | na | FLT3;CD3E | Amgen;BeiGene | na | Acute myeloid leukaemia | na | na | null | QV TLK ESGP TLV KPTE TLTLTCTL SGF S LNNA RMGVSWIR QPPGKC LEWLAHI F SNDEKSYSTSLK NRLTIS KDSSKT QVVLTMT NVDPVDTA TYYCARIVG YGSGW YGFFD YWGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAAS TLQSGVPS RF SGSGSGT EFTLTISS LQPEDF ATYYCL QHNSYP LTF GCGT KVEI K |
Empasiprubart | Whole mAb | G1 | Kappa | TBC | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQATGQGLEWIGDINPNYESTGYNQKFKGRATMTVDKSISTAYMELSSLRSEDTAVYYCAREDDHDAFAYWGQGTLVTVSS | DNVLTQSPDSLAVSLGERATISCRASKSVRTSGYNYMHWYQQKPGQPPKLLIYLASNLKSGVPDRFSGSGSGTDFTLTISSLQAEDAATYYCQHSRELPYTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | C2 | TBC | TBC | TBC | TBC | TBC | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT DYN MDWVRQ ATGQGL EWIG DINPNYESTGYNQKFKG RATMTV DKSI STAYMELS SLRSEDT AVYYCA REDDHDA FAYW GQG TLVTV SS | DNV LT QSPDS LAVS LGER ATISCR ASKS V RTSGY NYMHWYQ QKPGQPP KLLIYLA SNLKSGVPDRFSGSGSGTD FTLTISS LQAEDAA TYYCQ HSRELPY T FGQGT KLEI K |
Enapotamab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK | na | na | null | null | null | 2,017 | 2018 | AXL | Genmab | na | na | Solid tumours | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMNWVR QAPGKG LEWVST TSGSGA STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKIWIAFDI WGQG TMVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP EDF AVYYC QQ YGSSPYTFGQGT KLEI K |
Enavatuzumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAEIRLKSDNYATHYAESVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYYADAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIK | na | na | null | null | null | 2,010 | 2011 | TNFRSF12A | PDL BioPharma;Abbott Laboratories | na | na | Solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMSWVR QAPGKGL EWVAEIRLK SDNYA THYAES VKG RFTISR DDSKNS LYLQMNS LRAEDT AVYYCTGYY ADAMDYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQSVSTSSY SYMHWYQ QKPGKAP KLLIKYA SNLESGVPS RF SGSGSGTD FTLTISS LQPEDF ATYYC QHS WEI P YT FGGG TKVEI K |
Encelimab | Whole mAb | G4 | Kappa | Phase-I | Active | EVQLVQSGAEVKKPGATVKISCKASGFSIKDDYIHWVQQAPGKGLEWMGWIDAMNDDSQYSSKFQGRVTITVDTSTNTAYMKLSSLRSEDTAVYYCTYAFGGYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSDSNTYLHWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPYAFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | LAG3 | Anaptys Bio;TESARO | na | Solid tumours | na | na | null | E VQLVQ SGA EVK KPGA TVKISCK ASGF SI KDD YIHWVQQ APGKGL EWMGWID AMNDDSQYSSKFQG RVTITVD TSTN TAYMKLSS LRSEDT AVYYCTYAF GGYWGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISC RSSQ SLVH SDSNT YLHWYLQ KPGQSP QLLIYLVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFC GQSTHVPYAFGGG TKVEI K |
Enfortumab | Whole mAb ADC | G1 | Kappa | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK | na | na | null | null | null | 2,013 | 2014 | PVRL4 | Agensys;Seattle Genetics | Urogenital cancer | Bladder cancer;Prostate cancer;Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YNM NWVR QAPGKGL EWVSYIS SSSS TIYYA DSVKG RFTISR DNAKNS LSLQMN SLRDEDT AVYYCARAYYY GM D VWGQG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQGIS GWLAWYQ QKPGKAP KFLIYAA STLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QANSFPPTFGGGT KVEI K |
Englumafusp | Fusion Protein | G1 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYLNWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLLEDPYTFGQGTKLEIK | na | na | null | null | null | 2,021 | 2022 | CD19 | Roche | na | B cell Lymphoma | na | na | (June '22: Corrected CDRH2 sequence. Aug '22: WHO changed name from ensomafusp to englumafusp in PL127) | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYIMHWVR QAPGQGL EWMGYI NPYNDGSKY TEKF QG RVTM TSDTS ISTAYMELSR LRSDDT AVYYC ARGT YYY GPQ LF DYWGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISC KSSQ SLE TSTGT TYLNWYL QKPGQSP QLLIYRVSK RFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQL LEDPYTFGQGT KLEI K |
Enibarcimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGTTVTVSS | DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | ADM | Adrenomed | na | Septic shock;Cardiogenic shock;COVID-19 | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFSRYWIEWVR QAPGQG LEWIGEI LPGSGSTNYNQK F QG RVTITA DTSTS TAYMELS SLRSEDT AVYYC TEGY E YDG FDY WGQG TTVTVS S | D VVLT QSPLSLP VT LGQP ASISC RSSQ SIVYS NGN TYLEWYLQ RPGQSP RLLIYRVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHIP YTF GGG TKLEI K |
Enoblituzumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS | DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2017 | CD276 | MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | na | Prostate cancer;Solid tumours;Head and neck cancer | Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS F GMHWVRQ APGKG LEWVAYIS SDSS AIYYAD TVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYC GRGREN IYY GS RLDY WGQG TTVTVS S | DI QLT QSPS FLSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGKAPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYCQ QYNNYPF T FGQGT KLEI K |
Enokizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK | na | na | null | null | null | 2,010 | 2011 | IL9 | Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune | na | na | Asthma | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSYYWIEWVR QAPGQG LEWMGEI LPGSGTTNPNEKFK GRVTITA DESTS TAYMELSS LRSEDT AVYYCAR ADYYGSD YVKFDY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQH VITHVTWYQ QKPGKAP KLLIYG T SY SYSGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYCQQF YEYPL T FGGG TKVEI K |
Enoticumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPPTFGGGTKVEIK | na | na | null | null | null | 2,012 | 2013 | DLL4 | Regeneron Pharmaceuticals;Sanofi | na | na | Solid tumours | VelocImmune Mouse | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS YG MHWVRQ APGKGL EWVSFLWY DGTNKN YVESV K GRFTISR DNSKN MLYLEMN SLRAEDT AVYYCA RDHDFRSGYEG WF DPWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ HRSNWPPTFGGG TKVEI K |
Ensituximab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS | QVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK | na | na | null | null | null | 2,010 | 2011 | MUC5AC | Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine | na | Colorectal cancer;Pancreatic cancer | na | na | null | QV QLK ESGPDLVAPSQ SLSITCTV SGF S LS KFGVNWVR QPPGKGL EWLGVIW GDGSTSYNSG LISRLSI SKENSKS QVFLKL NSLQADDT ATYYCV KPGGDYWGHG TSVTVS S | Q VVLT QSP VIMS ASPGE KVTMTCS ASSS ISYMYWYQ QKPGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISN MEAGDA ATYYCH QRDSYPW TF GGGT NLEI K |
Enuzovimab | Whole mAb | G4 | Kappa | Phase-I | Active | EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDLQELGSLDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQEANSFPYTFGQGTKLEIK | na | na | 7cjf:AB | null | null | 2,021 | 2022 | SARS-CoV-2 Spike RBD | ABL Bio;HiFiBiO Therapeutics | na | COVID-19 | na | na | null | E VQLVES GGG LI QPGG SLRLSC AASG FIVS SNY MSWVR QAPGKGL EWVSIIYS GGS TFYA DSVKG RFTISR DNSKN TLYLQMNSLRV EDT AVYYCA RD LQE LGSLD Y WGQG TLVTV SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DFA TYYC QEANSFPY T FGQGT KLEI K |
Envafolimab | Single Domain Variable Fragment;H | G1 | na | Approved | Active | QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS | na | na | na | null | null | null | 2,018 | 2019 | PDL1 | Alphamab;3D Medicines;Sun Yat-Sen University | Solid tumours | Biliary cancer;Breast cancer;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma | na | na | (Oct '22) Sequence fixed to contain the full DJ/J regions. | Q VQLVES GGG LV QPGG SLRLSC AASGKMSS RRC M A W F R QAPGK ERERVAKL LT TSGS TYLA DSVKG RFTISR DNSKN TVYLQMN SLRAEDT AVYYCA ADSFEDPT CTLVT SSGA FQYW GQG TLVTV SS | null |
Epacmarstobart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWITWVKQAPGQGLEWIGDIYPGSGSTNHIEKFKSKATLTVDTSISTAYMELSRLRSDDTAVYYCATGYGSSYGYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYTAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHQYGPPFTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | SIRPA | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWITWVK QAPGQG LEWIGDI YPGSGSTNH IEKF KSK ATLTVD TSI STAYMELSR LRSDDT AVYYCA TGYGSSYG YFD YWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASEN IYSYLAWY QQKPGKAP KLLIYTAKT LAEGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYCQ HQYGPPF T FGQGT KLEI K |
Epcoritamab | Bispecific mAb | G1;G1 | Lambda;Kappa | Phase-III | Active | EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL | EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK | None;None | None;None | None;3giz:HL/6y92:CD:HL | 2,019 | 2020 | CD3E;MS4A1 | Genmab | na | Haematological malignancies;Diffuse large B-cell lymphoma;Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma | na | na | Second Fv closely related to Ofatumumab | E VKLVES GGG LV QPGG SLRLSC AASGF TFNTYAMNWVR QAPGKG LEWVARIR SKYNNY ATYYA DSVKD RFTIS RDDSKS SLYLQM NNLKTEDT AMYYCVRH GNFGNS YVSWFAYW GQG TLVTVS S | QA VVTQ EP SFSV SPGG TVTLTCR SSTGA VTT SNYAN WVQ QTPGQA FRGLI GGTNKRAPGVPA RFSGSL IGDK AALTIT GAQADDE SIYFCALWY SN LWVF GGGT KLTV L |
Epratuzumab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS | DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK | na | na | null | 5vkk:AB:HL/5vl3:EF:AB:HL:CD | null | 1,999 | 2000 | CD22 | Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB | na | na | Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTSYWLHWVR QAPGQG LEWIGYI NPRNDYTEYNQNFKDK ATITA DESTN TAYMELS SLRSEDT AFYFCA RRDI TTFYW GQGT TVTVS S | DI QLT QSPSS LSA SVGD RVTMSC KSSQ SVLYS ANHKN YLAWYQ QKPGKAP KLLIYWA STRESGVPS R FSGSGSGTD FTFTIS SLQ PEDIATY Y CHQYL SSW T FGGGT KLEI K |
Eptinezumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS | QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | CALCA&CALCB | Alder Biopharmaceuticals | Migraine | Cluster headache | na | na | null | E VQLVES GGG LV QPGG SLRLSCAV SG ID LSGY YMNWVR QAPGKGL EWVGVIGI NGA TYYASW AKG RFTISR DNSKT TVYLQM NSLRAEDT AVYFCA RGD I WGQG TLVTVS S | QVLTQSPSS LSA SVGD RVTINC QASQSVYHN TYLAWYQ QKPGKVPK QLIYD ASTLASGVPS RF SGSGSGT DFTLTISS LQPEDV ATYYCLGSYD CTNGD CFVF GGG TKVEI K |
Eramkafusp | Whole mAb Fusion | G1 | Kappa | Phase-I | Discontinued | QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA | QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK | na | na | null | 2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM | null | 2,020 | 2021 | CD20 | Spectrum Pharmaceuticals;ImmunGene | na | na | Non-Hodgkin's lymphoma | na | Possibly a Rituximab biosimilar. (June '22): Corrected IMGT VH 128 S->A | QV QLQ QPGA ELV KPGA SVKMSCK ASGY TFTSYNMHWVK QTPGRG LEWIGAI YPGNGDTSYNQK F KG KATLTA DKSSST AYMQLS SLTSEDS AVYYCAR S T YYGGD WYFNVW GAGT TVTVS A | Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYIHWFQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQW TSNPPTFGGGT KLEI K |
Erenumab | Whole mAb | G2 | Lambda | Approved | NFD | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS | QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL | na | na | 6umg:HL:hl/6umh:HL:hl/6umi:HL/6umj:HL | null | null | 2,016 | 2017 | CALCRL | Amgen;Novartis | Migraine | na | Hot flushes | Abgenix XenoMouse | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSFGMHWVRQ APGKGL EWVAVIS FDGS IKYSVD SVKG RFTISR DNSKN TLFLQMN SLRAEDT AVYYCA RDRL NYY DSSGY YHYKYYGMAVW GQGT TVTVS S | QSVLTQPPS V SAAPGQ KVTISC SGSSSNIGNN YVSWY Q QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS TTLGITG LQTGDEAD YY CGTWDSR LSAVVF GGGT KLTV L |
Erfonrilimab | Bispecific Single Domains (VH-VH'-CH) | G1 | na;na | Phase-III | Active | QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS | na | QVQLVESGGGLVQPGGSLRLSCAASGYIYSAYCMGWFRQAPGKGLEGVAAIYIGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADVIPTETCLGGSWSGPFGYWGQGTLVTVSS | na | None;6rqm:B | None;None | None;None | 2,020 | 2021 | CD274;CTLA4 | Alphamab | na | Non-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma | na | na | (June '22: Corrected FWH1 sequence) | Q VQLVES GGG LV QPGG SLRLSC AASGKMSS RRC M A W F R QAPGK ERERVAKL LT TSGS TYLA DSVKG RFTISR DNSKN TVYLQMN SLRAEDT AVYYCA ADSFEDPT CTLVT SSGA FQYW GQG TLVTV SS | null |
Erlizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRFMDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIK | na | na | 2fgw:HL | null | null | 2,000 | 2001 | CD18 | Genentech;PDL Biopharma; Roche | na | na | Myocardial infarction;Shock | na | null | E VQLVES GGG LV QPGG SLRLSC ATSGY TFTEYTMHWMR QAPGKG LEWVAGI NPKNGGTSHNQRF M D RFTISV DKSTS TAYMQMN SLRAEDT AVYYCARW RGLNYG FDVRYFDV WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD INNYLNWYQ QKPGKAP KLLIYYT STLHSGVPSRFSGSGSGTD YTLTIS SLQ PEDFAT YYC QQGNTLPPTFGQGT KVEI K |
Etaracizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK | na | na | null | null | null | 2,008 | 2009 | ITGAV_ITGB3 | Applied Molecular Evolution;MedImmune | na | na | Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS YDM SWVR QAPGKG LEWVAKVS SGGGS TYYLD TVQG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR HLHGS FAS WGQG TTVTVS S | E IVLT QSPA TLSL SPGE RATLSCQ ASQS ISNFLHWYQ QRPGQAP RLLIRYR SQSISGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYC QQSGSWP LTF GGG TKVEI K |
Etesevimab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS | DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK | na | na | 7c01:CD:HL | null | null | 2,020 | 2021 | SARS-CoV-2 Spike RBD | Eli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences | COVID-19 | na | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TVS SN YMSWVR QAPGKGL EWVSVIY SGGS TFYA DSVKG RFTIS RDNSMN TLFLQM NSLRAEDT AVYYCARVL PMYGDY L D Y WGQG TLVTVS S | DI VMT QSPSS LSA SVGD RVTITCR ASQ SISRYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTPPEY T FGQGT KLEI K |
Etevritamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I | Discontinued | QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSS | DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | EGFR;CD3E | Amgen | na | na | Glioblastoma | na | null | Q VQLVES GGG VVQ SGR SLRLSC AASGF TFRNYGMHWVRQ APGKC LEWVAVIWY DGSDK YYAD SVRG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDGY DILT GNPRDFDYWGQG TLVTV SS | DT VMT QTPLSSH VT LGQPA SISC RSSQ SLV HSDGN TYLSWLQ QRPGQPP RLLIYRISR RFSGVPDRFSGSGAGT DFTLEISRVE AEDV GVYYCMQ STHVPRTFGCG TKVEI K |
Etigilimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | TIGIT | OncoMed Pharmaceuticals | na | Solid tumours | na | na | null | QV QLQ ESGPGL V KPSE TLSLTCAV SGY SI TSDY AWNWIR QPPGKGL EWIGYISY SGSTSYNPSL RSRVTISR DTSKN QFFLKLS SVTAADT AVYYCA RRQVG LGFAYW GQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQD VSTA VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QHYSTPW T FGQGT KVEI K |
Etokimab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLMQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGTIYPRNSNTDYNQKFKARVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPLYYYLTSPPTLFWGQGTLVTVSS | DIQLTQSPSFLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAKTYPFTFGSGTKLEIK | na | na | null | null | null | 2,018 | 2019 | IL13 | AnaptysBio | na | na | Asthma;Atopic dermatitis;Peanut hypersensitivity;Rhinosinusitis | na | null | Q VQLMQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGTIY PRNSNTDYNQ KFKARVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RP LYYYL TSPP TLFW GQG TLVTV SS | DI QLT QSPS FLSA SVGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWA STRHTGVPSRFSGSGSGT EFTLTIS SLQP EDFAT YYC QQAKTYP FTF GSGT KLEI K |
Etrolizumab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | ITGA4_ITGB7&ITGAE_ITGB7 | Genentech;Roche | na | Crohn's disease;Ulcerative colitis | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASG FFIT NNY WGWVRQ APGKGL EWVGYISY SGSTSYNPSLK SRFTISR DTSKN TFYLQMNS LRAEDT AVYYCA RTGSSG YFDFW GQG TLVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASES VDDLLHWYQQ KPGKAP KLLIKYA SQSISGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYC QQGNSLPNTFGQGT KVEI K |
Evinacumab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK | na | na | null | null | null | 2,014 | 2015 | ANGPTL3 | Regeneron Pharmaceuticals;Sanofi | Hyperlipoproteinaemia type II | Hypertriglyceridaemia | na | na | null | E VQLVES GG GVI QPGG SLRLSC AASGFT F DDY AMNWVR QGPGKGL EWVSAI SGDGGS TYYA DSVKG RFTISR DNSKN SLYLQMN SLRAED TAFFYCA KDLRN TIFGVVI PDAF DI WGQG TMVTVS S | DIQ M TQSPS TLSAS VGD RVTITCR ASQS IRSWLAWYQ QKPGKAP KLLIYKA SSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FA TYYCQ QYNS YSYTF GQGT KLEI K |
Evolocumab | Whole mAb | G2 | Lambda | Approved | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS | ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL | na | na | null | null | null | 2,012 | 2013 | PCSK9 | Amgen;Amgen Astellas BioPharma;University Hospital Inselspital | Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke | Hyperlipidaemia;Coronary artery disease;Dyslipidaemias | na | Abgenix XenoMouse | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TLTSYGISWVRQ APGQGL EWMGWVSFY NGNTN YAQKLQ GRG TMT TDPSTST AYMELRSL RSDDT AVYYCA RGYGM DV WGQG TTVTVS S | ESALTQPA SV SGSPGQ SITISCT GTSSDVGGY NSVSWYQ QHPGKAP KLMIYEV SNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYC NSYTST SMVF GGGT KLTV L |
Evunzekibart | Whole mAb | G4 | Kappa | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFNFGYSYMSWVRQAPGKGLEWVSSIGSTSSHTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVYSSPGIDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSIGSTLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYTWVPFTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | TNFRSF9 | TBC | TBC | TBC | TBC | TBC | null | E VQLLES GGG LV QPGG SLRLSC AASGFN F G YSYMSWVR QAPGKG LEWVSS IGSTSSH TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCARVY SSPGID Y WGQ GTLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQSIGS TLNWYQ QKPGKAP KLLIYG ASSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQY YTWVPFT FGQGT KLEI K |
Exbivirumab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | QVQLVESGGGVVQPGGSLRLSCAPSGFVFRSYGMHWVRQTPGKGLEWVSLIWHDGSNRFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCARERLIAAPAAFDLWGQGTLVTVSS | SYVLTQPPSVSVAPGKTARISCGGNNIGTKNVHWYQQKPGQAPVLVVYADSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSVSYHVVFGGGTTLTVL | na | na | null | null | null | 2,004 | 2005 | Hepatitis B Surface Antigen | XTL Biopharmaceuticals;Yeda | na | na | Hepatitis B infection | na | null | Q VQLVES GGG VV QPGG SLRLSC APSG FVFRSY G MHWVRQ TPGKGL EWVSLIWH DGSNR FYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AMYFCA RE RLIA APAA FD LWGQG TLVTVS S | SY VL TQPPS VSV APGK TARISC GGNNIGTK NVHWYQ QKPGQAP VLVVYA DSDRPSGIPERFSGSNSGN TATLTISRVE AGDE ADYYCQVW DSV SYHVVF GGGT TLTV L |
Exidavnemab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIWRGGSTDYSAAFMSRLTISKDTSKNQVSLKLSSVTAADTAVYYCAKLLRSVGGFADWGQGTMVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQTIVHNNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGQGTKLEIK | na | na | null | null | null | 2,021 | 2022 | SNCA | AbbVie | na | SNCA | na | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SG FSLTSYGVHWIR QPPGKGL EWIGVIWR GGSTDYS AAFMSRLTIS KDTSKN QVSLKLSS VT AADTAVYYCAKLLRS VGGFADWGQG TMVTV SS | DI VMT QSPLSLPVTPGEPA SISC RSSQ TIVH NNGN TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP FTF GQGT KLEI K |
Exlinkibart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFAGFEMHWVRQAPGQGLEWMGAIDPKTGGTDYNQKFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDLGYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDIRSNLNWYQQKPGGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQSEKLPRTFGGGTKVEIR | na | na | null | null | null | 2,022 | na | TNFRSF9 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFAGFEMHWVRQ APGQG LEWMGAI DPKTGGTDYNQKFKD RVTM TRDTS ISTAYMELS RLRSDDT AVYYCA RDLGY FDV WGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCR ASQDI RS NLN W YQ QKPGGA VKLLIYYT SRLHSGVPS RF SGSGSGTD YTLTISS LQP EDFAT YFCQ QSEKLPRTFGGGT KVEI R |
Ezabenlimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVMLVESGGGLVQPGGSLRLSCTASGFTFSKSAMSWVRQAPGKGLEWVAYISGGGGDTYYSSSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSNVNYYAMDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATMSCRASENIDVSGISFMNWYQQKPGQAPKLLIYVASNQGSGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQSKEVPWTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | PDCD1 | Boehringer Ingelheim | na | Solid tumours;Squamous cell cancer;Colorectal caner;Head and neck cancer;Non-small cell lung cancer | na | na | (June '22: Corrected CDRH3/CDRL3 sequences) | E VMLVES GGG LV QPGG SLRLSCT ASGF TFS KSA MSWVR QAPGKG LEWVAYIS GGGGDT YYS SSVK GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCA RHSNV NYYAMD YWGQG TLVTVS S | E IVLTQ SPA TLSL SPGER ATMSCR ASENI DV SG ISFMNWY QQKPGQAP KLLIYVA SNQGSGIP ARFS GSGSGT DFTLTISR LEPED FAVYYCQ QSKEVPW T FGQGT KLEI K |
Faricimab | Bispecific mAb | G1;G1 | Kappa;Lambda | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL | 1cz8:HL:YX;None | None;None | 1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC | 2,017 | 2018 | VEGFA;ANGPT2 | Chugai Pharmaceutical;Roche | Diabetic macular oedema;Wet age-related macular degeneration | Diabetic retinopathy;Retinal oedema | na | Dual-Affinity Re-Targeting Technology | null | E VQLVES GGG LV QPGG SLRLSCA ASGYDF THYGMNWVR QAPGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPYYYGTS HWYFDV WGQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K |
Farletuzumab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS | DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK | na | na | null | null | null | 2,008 | 2009 | FOLR1 | Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd | na | Ovarian cancer;Non-small cell lung cancer | Solid tumours | na | null | E VQLVES GGG VV QPGR SLRLSCS ASGF TFS G YGLSWVRQ APGKG LEWVAMIS SGGS YTYYA DSVKG RFAISR DNAKN TLFLQM DSLRPEDT GVYFCAR HGDDPA WFAYW GQGT PVTVS S | DI QLT QSPSS LSAS VGD RVTITCSVS SSISSNNL HWYQ QKPGKAPKP WIY GTSNLASGVPS R FSGSGSGT DYTFTISS LQ PEDIA TYYC QQWSSYP YMYTF GQGT KVEI K |
Fasinumab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS | DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | NGFB | Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi | na | Back pain;Pain | na | VelocImmune Mouse | null | Q VQLVQ SGA EVK KPGA SVKVSCKV SG FTLTELSIHWVR QAPGKG LEWMG G F DPEDGE TIYAQKF QG RVTMT EDTSTDT AYMELTSL RSEDT AVYYCSTIFGVVTN FDNWGQG TLVTVS S | DI QMT QSPSS LS ASAGD RVTITCR AS QAIRN DLG W Y QQKPGKAPK RLIYAAFN LQSGVPS RF SGSGSGT EFTLTIS SLQ PEDLASYYCQQ YNRYPWTFGQGT KVEI K |
Favezelimab | Whole mAb | G4 | Kappa | Phase-II | Active | QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | LAG3 | Merck | na | Non-small cell lung cancer;Haematological malignancies;Solid tumours | na | na | Favezelimab is the new name for Mavezelimab (PL123) | QM QLVQ SGPEVKKPGT SVKVSCK ASGY TFTD YN VDWVR QARGQ RLEWIGD INPNDGG TIYAQK FQE RVTITVD KSTS TAYMELS SLRSEDT AVYYCA RNY RWFG A M DHWGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISCK ASQSLDYEGDSDM NWYL QKPGQPP QLLIYG ASNLESGVPDRFSGSGSGT DFTLKISRVE AED VGVYYCQQ STEDPRTFGGG TKVEI K |
Fazpilodemab | Bispecific mAb | G1;G1 | Kappa;Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASDFSLTTYGVHWVRQAPGKGLEWLGVIWSGGSTDYNAAFISRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARDYGSTYVDAIDYWGQGTLVTVSS | DIVLTQSPDSLAVSLGERATINCRASESVESYGNRYMTWYQQKPGQPPKLLIYRAANLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPWTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFTSNYISWVRQAPGKGLEWVGEIDPYDGDTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCATGTDVMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK | None;None | None;None | None;None | 2,022 | na | KLB;FGFR1 | TBC | TBC | TBC | TBC | TBC | 3sob is 94% similar to FGFR1 binding arm | E VQLVES GGG LV QPGG SLRLSCA ASDFS LTTYGVHWVRQ APGKGL EWLGVIWS GGSTDYN AAFISRLTIS KDNSKN TVYLQMNS LRAEDT AVYYCA RDYGST YVDAIDY WGQG TLVTVS S | D IVLT QSPDS LAVS LGER ATINCR ASES VES YGN RYMTWYQ QKPGQPP KLLIYRA ANLQSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSNEDPW T FGQG TKVEI K |
Feladilimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | ICOS | GlaxoSmithKline | na | Solid tumours;Multiple myeloma;Non-small cell lung cancer;Head and neck cancer | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFT DY AMHWVRQ APGQGL EWMGLISIY SDHTNYNQ KFQGRVTITA DKSTS TAYMELS SLRSEDT AVYYC GRNNYGNY GWYFDV WGQG TTVTVS S | E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAP RLLIYD TSKLASGIP ARFS GSGSGTD YTLTISS LEPED FAVYYCF QGSGYPY TF GQGT KLEI K |
Felzartamab | Whole mAb | G1 | Lambda | Phase-III | Active | QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS | DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | CD38 | MorphoSys | na | Multiple myeloma;Membranous glomerulonephritis;Leukemia;Systemic lupus erythematosus | Non-small cell lung cancer | na | null | Q VQLVES GGG LV QPGG SLRLSC AASGF TFSSYYMNWVR QAPGKG LEWVS GISGDPSNT YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDLP LVYTGFAYW GQG TLVTVS S | DIELTQPPS VSV APGQ TARISC SGDNLR HYYVYWYQ QKPGQAP VLVIY GDSKRPSGIPERFSGSNSGN TATLTIS GTQAEDEAD YYCQT YTGGA SLVF GGGT KLTV L |
Fepixnebart | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCRSSQSIVHSTGNTYLEWYQQKPGQPPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFHGTHVPYTFGGGTKVEIK | na | na | 5kn5:AB | null | null | 2,022 | na | EREG | Eli Lilly and Company | na | Back pain;Neuropathic pain;Pain;Diabetic nephropathies | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTD A YINWVR QAPGQGL EWMGWI WPGP VITYY NPKFKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RREVLSPF AYW GQGT TVTVS S | D IVMT QSPDS LAVS LGER ATINC RSSQ SIVH STGN TYLEWYQ QKPGQPP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLTISS LQAED VAVYYCF HGTHVP YT FGGG TKVEI K |
Fezakinumab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS | QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL | na | na | null | null | null | 2,009 | 2010 | IL22 | Pfizer;Wyeth | na | na | Psoriasis;Rheumatoid arthritis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYYMHWVR QAPGQG LEWVGWI NPYTGS AFYAQK FRG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA REPEKFDSDDSDV W GR GTLVTVS S | QA VL TQPPSVSGAPGQ RVTISCT GSSSNIGAGY GVHWYQQ LPGTAP KLLIYG DSNRPSGVPDRFSGSKSGTS AS LAIT GLQAEDEAD YYCQS YDNSLS GYVF GGGT QLTV L |
Fianlimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | LAG3 | Regeneron Pharmaceuticals | na | Cancer | na | na | null | Q VQLVES GGG VV QPGR SLRLSCV ASGF TFSS Y GMHWVRQ APGKGL EWVAIIWY DGSNK YYAD SVKG RFTISR DNSKNT QYLQMNSL RAEDT AVYYCASVA TSGDFD YYGMDV WGQG TTVTVS S | E IVLT QSPA TLSL SPGER TTLSCR ASQR I S TYLAWY QQKPGQAP RLLIYD ASKRATGIP ARFS GSGSGTG FTLTIS SLEPED FAVYYCQ QRSNWP LTF GGG TKVEI K |
Ficlatuzumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS | DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK | na | na | null | null | null | 2,011 | 2012 | HGF | AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco | na | Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer | Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma | na | null | QV QLV QPGA EVK KPGT SVKLSCK ASGY TFTTYWMHWVR QAPGQG LEWIGEI NPTNGHTNYNQK F QG RATLTVD KSTS TAYMELSS LRSEDT AVYYCA RNYVGS IFD YWGQG TLLTVS S | D IVMT QSPDS LAM SLGE RVTLNCK ASEN VVSYVSWYQ QKPGQSP KLLIYG ASNRESGVPDRFSGSGSATD FTLTISSV QAEDVADYHCGQSYNYPY T FGQGT KLEI K |
Fidasimtamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC | None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,021 | 2022 | PDCD1;ERBB2 | Hanmi Pharmaceutical;Innovent Biologics | na | Solid tumours | na | na | (June '22: Corrected FWL4 sequence in LC1) | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLISA ASSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QANHLP FTF GGGT KVEI K |
Figitumumab | Whole mAb | G2 | Kappa | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS | DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK | na | na | null | null | null | 2,008 | 2009 | IGF1R | Pfizer | na | na | Breast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours | na | null | E VQLLES GGG LV QPGG SLRLSCT ASGF TFSSYAMNWVR QAPGKGL EWVSAI SGSGG TTFYA DSVKG RFTISR DNSR TTLYLQMN SLRAEDT AVYYCA KDLGWSDS YYYYYGMDV WGQG TTVTVS S | DIQ MT QFPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAAS RLHRGVPS R FSGSGSGT EFTLTIS SLQPEDF ATYYCL QHNSYPCSFGQGT KLEI K |
Finotonlimab | Whole mAb | G4 | Kappa | Phase-III | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKRLEWVATISGGGRDTYYSDSVKGRFTISRDNAKNNLYLQMNSLRAEDTAVYYCSRQYGTVWFFNWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVDSYGNSFMHWYQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAMYFCQQSKEVPWTFGQGTKVEIK | na | na | null | null | null | 2,020 | 2021 | PDCD1 | Sinocelltech | na | Hepatocellular carcinoma;Heavy and neck squamous cell carcinoma | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSS YG MSWVR QAPGK RLEWVATIS GGGRDT YYS DSVKG RFTISR DNAKNN LYLQMNS LRAEDT AVYYCS RQYG TVWFFN WGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVDSYGN SFMHWYQ QKPGQPP RLLIYAA SNQGSGVP ARFS GSGSGTD FTLTIS SLE PEDFA MYFC QQSKEVPW T FGQGT KVEI K |
Firivumab | Whole mAb | G1 | Kappa | Preclinical | Discontinued | QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASENIWNNLAWYQQKPGQAPRLLISGASTGATGVPSRFRGSGSRTEFTLTISSLQSEDFAIYFCQQYNSWPRTFGPGTKVEIK | na | na | null | null | null | 2,014 | 2015 | Influenza A HA | Celltrion | na | na | Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections | na | null | Q VQLVQ SGA EVK MPGS SVKVSC KTSG VFF SSH AISWVR QAPGQGL EWM GGISPMFGTT HYAQK FQG RVTITA DQSTT TAYMELTS LTSEDT AVYYCA RDGAGS YY PLN WF DPWGQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASEN IWNNLAWYQ QKPGQAP RLLIS GASTGATGVPSRFRGSGSR TEFTLTISS LQSED FAIYFCQ QYNSWPRTFGPGT KVEI K |
Fiztasovimab | Whole mAb | G1 | Lambda | TBC | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWGWIRQPPGKGLEWIGEINHSGSANSNPSLKSRVTMSVDTSKNQFSLKVSSVTAADTAVYFCARVTRDLEWIPGDYYMDVWGKGTTVTVSS | QSVLTQPPSASGTPGQRVSISCSGSLSNIGTNYVYWYQQLPGTAPKLLIFKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGYVFGTGTKVTVL | na | na | null | null | null | 2,022 | na | HHV gB AD-1 | TBC | TBC | TBC | TBC | TBC | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWGWIR QPPGKGL EWIGEIN HSGSANSNPSLK SRVTMSVD TSKN QFSLKVSSV TAADT AVYFCARVT RDLE W IPGD YYMDVW GKG TTVTVS S | QSVLTQPPSASGTPGQ RVSISC SGSLSNIGTN YVYWYQ QLPGTAP KLLIFK NNQRPSGVPDRFSGSKSGTS A SLAI SGLRSEDEAD YYCAAW DDSLNG YVF GTGT KVTV L |
Flanvotumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGSELKKPGASVKISCKASGYTFTSYAMNWVRQAPGQGLESMGWINTNTGNPTYAQGFTGRFVFSMDTSVSTAYLQISSLKAEDTAIYYCAPRYSSSWYLDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLMYTFGQGTKLEIK | na | na | null | null | null | 2,011 | 2012 | TYRP1 | ImClone Systems;Eli Lilly | na | na | Malignant melanoma | na | null | Q VQLVQ SGS E LKKPGA SVKISCK ASGY TFTSYAMNWVR QAPGQGL ESMGWIN TNTGNPTYAQGF TGRFVFSM DTSV STAYLQISS LKAEDT AIYYC APRYSSS WYLDY WGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSN WLMYTF GQGT KLEI K |
Fletikumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | na | na | null | null | null | 2,013 | 2014 | IL20 | ZymoGenetics;Novo Nordisk | na | na | Psoriasis;Rheumatoid arthritis | na | null | Q VQLVQ SGA EVK RPGA SVKVSCK ASGY TF TND IIHWVR QAPGQ RLEWMGWIN AGYGNTQYSQNFQD RVSITR DTSAST AYMELISLR SEDT AVYYCA REPLWFGESSPHDYY GMDV WGQG TTVTVS S | AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K |
Flotetuzumab | Bispecific scFv with Crossover | na;na | Kappa;Lambda | Phase-I/II | Discontinued | EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGDIIPSNGATFYNQKFKGRVTITVDKSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS | DFVMTQSPDSLAVSLGERVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,017 | 2018 | IL3RA;CD3E | MacroGenics;Servier | na | na | Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma | Dual-Affinity Re-Targeting Technology | null | E VQLVQ SGA EL KKPGA SVKVSCK ASGY TFTDYYMKWVR QAPGQGL EWIGDII PSNGA TFY NQKFKG RVTITVD KSTS TAYMELS SLRSEDT AVYYC ARSHL LRASWFAYW GQG TLVTVS S | DF VMT QSPDS LAVS LGE RVTMSC KSSQS L LNSGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYSYPY T FGQGT KLEI K |
Fontolizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK | na | na | null | 1t3f:BA/1t04:DC:BA | null | 2,002 | 2003 | IFNG | PDL BioPharma | na | na | Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis | na | null | Q VQLVQ SGA EL KKPGS SVKVSCK ASG YIFT SSW INWVK QAPGQG LEWIGRI DPSDGE VHY NQDFKDK ATLTVD KSTN TAYMELS SLRSEDT AVYYCA RGFLPW F ADWGQG TLVTVS S | DIQ MT QSPS TLSAS VGD RVTITCK ASENVD TYVSWYQ QKPGKAP KLLIYG ASNRYTGVPSRFSGSGSGTD FTLTISS LQPDDF ATYY CGQSYNYPF T FGQGT KVEV K |
Foralumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK | na | na | null | null | null | 2,010 | 2011 | CD3E | Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences | na | Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus | Transplant rejection;Type 1 diabetes mellitus | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF KFS G YGMHWVRQ APGKGL EWVAVIWY DGSK KYYVD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR QMGY WHFDL WGRG TLVTV SS | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPL TF GGG TKVEI K |
Foravirumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGGGTKVEIK | na | na | null | null | null | 2,008 | 2009 | RV Antigenic Site III | Crucell;Sanofi Pasteur | na | na | Rabies | Human Phage Display | null | Q VQLVES GGGAVQPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVILY DGSDK FYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKVAVA GT HFD YWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ LNSYPPTFGGGT KVEI K |
Forimtamig | Bispecific mAb with Domain Crossover | G1;G1 | Kappa;Lambda | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSISGINLMNWYQQKPGQQPKLLIYHASILASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTRESPLTFGQGTRLEIK | EVQLLESGGGLVQPGGSLRLSCAASGFQFSSYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHTTFPSSYVSYYGYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,022 | na | GPRC5D;CD3E | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTD A YINWVR QAPGQGL EWMGWI WPGP VITYY NPKFKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RREVLSPF AYW GQGT TVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQ SVSIS G INLMN W Y QQKPGQQP KLLIYHASILA SGIPDRFSGSGSGTD FTLTISR LEPED FAVYYCQ QTRESPL T FGQG TRLEI K |
Fremanezumab | Whole mAb | G2 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIK | na | na | null | null | null | 2,016 | 2017 | CALCA&CALCB | Rinat Neuroscience;Teva Pharmaceutical Industries | Migraine | Fibromyalgia;Headache;Interstitial cystitis | Cluster headache | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF S NYWISWVR QAPGKG LEWVAEIR SESDASAT HYAE A V KG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCLAYF DY GL AIQ NYWGQG TLVTV SS | E IVLTQ SPA TLSL SPGE RATLSCK ASKR VTTYVSWYQ QKPGQAP RLLIYG ASNR YLGI P ARF SGSGSGT DFTLTIS SLEPED FAVYYCS QSYNYPY T FGQGT KLEI K |
Freneslerbart | Whole mAb | G4 | Kappa | TBC | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFRNYNINWVRQAPGKGLEWVSLISGSSSYIYYADSVKGRFTVSRDNAKNSLYLQMNSLRAEDTAVYYCARRTLSYYVMDVWGQGTTVTVSS | DIQVTQSPSPLSASVGDRVTITCRASQGISNYLAWYQQKPGRVPQLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | Fel d 1 | TBC | TBC | TBC | TBC | TBC | Antigen: Felis silvestris catus (domestic cat) allergen 1 | E VQLVES GGG LV KPGG SLRLSC AASGF TFRNYNINWVR QAPGKGL EWVSLI SGSSS YIYYA DSVKG RFTVSR DNAKN SLYLQMN SLRAEDT AVYYCA RRT LSYYVMDV WGQG TTVTVS S | DI QVT QSPSPLSASVGD RVTITCR ASQG ISNYLAWYQ QKPGRVP QLLIYA ASTLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDVATYYCQK YNSAPY T FGQGT KLEI K |
Fresolimumab | Whole mAb | G4 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS | ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK | na | na | null | 3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG | null | 2,009 | 2010 | TGFB | Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme | na | na | Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta | CAT Phage Display | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF SSN VISWVR QAPGQGL EWM GG VIPI VDIANYAQR FKG RVTITA DESTST TYMELS SLRSEDT AVYYC ASTL GL V LDAMD YWGQG TLVTV SS | ET VLT QSPG TLSL SPGE RATLSCRA SQSLGSS YLAWYQ QKPGQAP RLLIYG ASSRAPGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYADSPI TF GQGT RLEI K |
Frexalimab | Whole mAb | G1 | Kappa | TBC | Active | EVQLQESGPGLVKPSETLSLTCTVSGDSITNGFWIWIRKPPGNKLEYMGYISYSGSTYYNPSLKSRISISRDTSKNQFSLKLSSVTAADTGVYYCAYRSYGRTPYYFDYWGQGTTLTVSS | DIVMTQSPSFLSASVGDRVTITCKASSNLGHAVAWYQQKPGKSPKLLIYSASNRYTGVPDRFSGSGSGTDFTLTISSLQPEDFADYFCQQYDDYPYTFGGGTKLEIK | na | na | null | null | null | 2,022 | na | CD40LG | TBC | TBC | TBC | TBC | TBC | null | E VQLQE SGPGL V KPSE TLSLTCTVS GDSITN GFWIWIR KPPGNK LEYMGYISY SGS TYY NPSLK SRISIS RDTSKN QFSLKLSSVT AADTG VYYCAYR SYGRTP YYFDY WGQG TTLTVS S | DI VMT QSPS FLSA SVGD RVTITCK ASSNLG H AVAWYQ QKPGKSP KLLIYS ASNRYTGVPDRFSGSGSGTD FTLTIS SLQ PEDFADYFCQQ YDDYPY T FGGGT KLEI K |
Frovocimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFPFSKLGMVWVRQAPGKGLEWVSTISSGGGYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGISFQGGTYTYVMDYWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | PCSK9 | Eli Lilly | na | Hypercholesterolaemia | na | na | null | E VQLVES GGG LV KPGG SLRLSCA ASGFPFSK LGMVWVRQ APGKG LEWVSTIS SGGG YTY YPDSVK GRFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REGI SF QGG TYTYVMDY WGQG TLVTVS S | DI VMT QSPLSLPVTPGEPA SISCR SSKS LLH RNG ITYSYWYLQ KPGQSP QLLIYQL SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCYQ NLELPL TF GQGT KVEI K |
Frunevetmab | Feline Whole mAb | G1 | Kappa | Unknown | Active | QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA | DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK | na | na | null | null | null | 2,016 | 2017 | NGFB | Nexvet | na | Feline osteoarthritis | na | PETization Technology | null | Q VQLVE SGA ELV QPGE SLRLTCA ASGF S LTNNN VNWVRQ APGKG LEWM GG VWA GGATDYNSALK SRLTITR DTSKN TVFLQMHS LQSEDT ATYYCA RDGGYSSS TLYAMD AWGQG TTVTVS A | DIEMTQSPL SLSV TPGE SVSISCR AS EDIYNALAWYLQ KPGRSP RLLIYN TDTL H TGVPDRFSGSGSGTD FTLKISRVQ TEDV GVYFCQHYFH YPRTFGQGT KLEL K |
Fulranumab | Whole mAb | G2 | Kappa | Phase-III | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | na | na | null | 4m6o:HL | null | 2,010 | 2011 | NGFB | Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen | na | na | Pain;Back pain;Cancer pain;Musculoskeletal pain;Neuropathic pain | Abgenix XenoMouse | null | E VQLVES GGG LV QPGG SLRLSC AASGF TLRSYSMNWVR QAPGKGL EWVSYIS RSSH TIFYA DSVKG RFTISR DNAKN SLYLQMD SLRDEDTA MYYCARVY SSGW HV SDY F DYWGQ GILVTVS S | AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K |
Futuximab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS | DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK | na | na | null | null | null | 2,012 | 2013 | EGFR | Symphogen;Merck | na | Colorectal cancer;Glioma;Non-small cell lung cancer | Head and neck cancer;Oesophageal cancer | na | null | EV QLQ QPGS ELV RPGA SVKLSCK ASGY TFTSYWMHWVK QRPGQG LEWIGNI YPGSRSTNYDEKFKS KATLTVD TSSST AYMQLS SLTSEDS AVYYCT RNGD YYVSS GDAMDYWGQG TSVTVS S | DIQ MT QTTS SLS ASLGD RVTISCR TS QDIGNYLNWYQ QKPDGT VKLLIYYT SRLHSGVPSRFSGSGSGTD FSLTI NNVE QEDVATYFCQH YNTVPPTFGGGT KLEI K |
Galcanezumab | Whole mAb | G4 | Kappa | Approved | NFD | QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | CALCA&CALCB | Eli Lilly | Migraine;Cluster headache | na | Musculoskeletal pain | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF GN YWMQWVR QAPGQG LEWMGAIYE GTGK TVYIQK FAD RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR LSDYVSGFGYWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASKD ISKYLNWYQ QKPGKAP KLLIYYT SGYHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YC QQGDALPPTFGGGT KVEI K |
Galegenimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | HTRA1 | Roche | na | Age-related macular degeneration | na | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY KF TDSE MHWVRQ APGQG LEWI GGVDPETEGAAYNQKFKG RATITR DTSTS TAYLELS SLRSEDT AVYYCT RGYDYD YALDY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASSS VEFIHWYQ QKPGKAPKP LISA TSNLASGVPS R FSGSGSGT DFTLTISS LQPE DF ATYYCQ QWSSAPW TF GQGT KVEI K |
Galiximab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS | ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL | na | na | null | null | null | 2,003 | 2004 | CD80 | Biogen;Biogen Idec | na | na | Autoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis | na | null | QV QLQ ESGPGL V KPSE TLSLTCAV SGGSISGG YGWGWIR QPPGKGL EWIGSFY SSSGN TYY NPSLKS QVTIST DTSKN QFSLKL NSMTAADT AVYYCV RDRL FSVVGMVY NNW FDVW GPG VLVTVS S | ESALTQPPSVSGAPGQ KVTISC TGSTSNIGG YD LHWYQ QLPGTAP KLLIYD INKRPSGISDRFSGSKSGT AAS LAI TGLQTEDEAD YYCQ SYDSSLN AQVF GGGT RLTV L |
Gancotamab | scFv | na | Lambda | Phase-II | Discontinued | QVQLVESGGGLVQPGGSLRLSCAASGFTFRSYAMSWVRQAPGKGLEWVSAISGRGDNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMTSNAFAFDYWGQGTLVTVSS | QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGFKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL | na | na | null | null | null | 2,018 | 2019 | ERBB2 | Merrimack Pharmaceuticals;HERMES BioSciences | na | na | Breast cancer | na | null | Q VQLVES GGG LV QPGG SLRLSC AASGF TFRSYAMSWVR QAPGKG LEWVSAI SGRGDN TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK MTSNA FAFDY WGQG TLVTVS S | QSVLTQPPSVSGAPGQ RVTISCT GSSSNIGAGY GVHWYQQ LPGTAP KLLIYG NTNRPSGVPDRFSGFKSGTS A SLAIT GLQAEDEAD YYCQS YDSSLSG WVF GGGT KLTV L |
Ganitumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS | DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | IGF1R | Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center | na | Ewing's sarcoma;Solid tumours;Rhabdomyosarcoma | Breast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer | na | null | QV QLQE SGPG LV KPSG TLSLTCAV SGGSISSSN WWSWVR QPPGKGL EWIGEIYH SGSTNYNPSLK SRVTISVD KSKN QFSLKLSSV TAADT AVYYCARW TGRTDA FDIW GQG TMVTVS S | DV VMT QSPLSLPVTPGEPA SISC RSSQS LLH SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCM QGTHWP LTF GQGT KVEI K |
Gantenerumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS | DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK | na | na | 5csz:HL:AB | null | null | 2,012 | 2008 | APP | MorphoSys;Chugai Pharmaceutical;Roche | na | Alzheimer's disease | na | na | null | Q VELVE SGGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI NASGT RTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA RGKGNTHKPY GYVRYFDV WGQG TLVTVS S | D IVLTQ SPA TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGVP ARFS GSGSGT DFTLTIS SLE PEDFAT YYCLQIY NMP ITF GQGT KVEI K |
Garadacimab | Whole mAb | G4 | Lambda | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYIMQWVRQAPGKGLEWVSGIDIPTKGTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALPRSGYLISPHYYYYALDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGRNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLRGVFGGGTKLTVL | na | na | null | null | null | 2,018 | 2019 | F12 | CSL Behring | na | Hereditary angioedema;COVID-19 | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SKY IMQWVR QAPGKGL EWV SGI D IPTKG TVYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR ALPRSG YLI SPH YYYYALDV WGQG TTVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSSSN IGRNYVYWYQQ LPGTAP KLLIYS NNQRPSGVPDRFSGSKSGT SASLAI SGLRS EDEADYYCAAWDASLRGV FGGGT KLTV L |
Garetosmab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | INHBA | Regeneron Pharmaceuticals | na | Fibrodysplasia ossificans progressiva;Osteroporosis | Musculoskeletal disorders | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SGGSFS SHFWSWIR QPPGKGL EWIGYILYT GGTSFNPSLK SRVSMSV GTSKN QFSLKLSS VTAADT AVYYCAR ARSG ITFTGIIV PGS FDIW GQG TMVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K |